Table 6.
Best overall response per patient characteristics.
| Factor | Category | N | Responders (CR + PR), N (%) | Odds ratio (95% CI)a |
|---|---|---|---|---|
| Efficacy analysis population | 88 | 26 (29.55) | ||
| ECOG performance status | 0 | 25 | 13 (52.00) | – |
| 1 | 48 | 11 (22.92) | 0.27 (0.10, 0.77) | |
| 2 | 7 | 0 | NE | |
| 3 | 6 | 2 (33.33) | 0.46 (0.07, 2.99) | |
| 4 | 2 | 0 | NE | |
| Brain metastasis | Absent | 35 | 11 (31.43) | – |
| Present | 52 | 15 (28.85) | 0.88 (0.35, 2.25) | |
| Unknown/not reported | 1 | 0 | – | |
| No. of prior lines of therapy | 0 | 0 | 0 | NE |
| 1 | 1 | 0 | NE | |
| 2 | 10 | 5 (50.00) | NE | |
| 3 | 29 | 7 (24.14) | NE | |
| ≥ 4 | 48 | 14 (29.17) | NE | |
| Prior therapies | Crizotinib | 86 | 26 (30.23) | – |
| Alectinib | 84 | 24 (28.57) | – | |
| Combination chemotherapy including a platinum-based drug (e.g., platinum doublet) | 73 | 22 (30.14) | – | |
| Cancer immunotherapy | 7 | 3 (42.86) | – | |
| Other chemotherapy | 27 | 9 (33.33) | – | |
| Age | < 75 years | 80 | 23 (28.75) | – |
| ≥ 75 years | 8 | 3 (37.50) | – | |
| < 65 years | 52 | 13 (25.00) | – | |
| ≥ 65 years | 36 | 13 (36.11) | – |
CI confidence interval; CR complete response; ECOG Eastern Cooperative Oncology Group; NE not estimable; PR partial response.
aUnknown/not recorded patients were excluded from the calculation of odds ratio.